|
2025
|
Invention
|
Combination cancer immunotherapies with arginine depletion agents.
Provided are arginine depleti... |
|
2023
|
Invention
|
Modified arginine deiminases.
Provided are modified arginine deiminase (ADI) proteins, including... |
|
|
Invention
|
Modified arginine deiminases. Provided are modified arginine deiminase (ADI) proteins, including ... |
|
2021
|
Invention
|
Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatm... |
|
2018
|
Invention
|
Protein conjugates. Provided are conjugates of an arginine deiminase (ADI) and a Tumor Necrosis F... |
|
2017
|
Invention
|
Formulations of pegylated arginine deiminase. Provided are lyophilized formulations comprising pe... |
|
|
Invention
|
Methods of treatment with arginine deiminase. The present invention relates generally to methods ... |
|
|
Invention
|
Combination cancer immunotherapies with arginine depletion agents. Provided are arginine depletio... |
|
2015
|
Invention
|
Arginine deiminase with reduced cross-reactivity toward adi-peg 20 antibodies for cancer treatmen... |
|
|
Invention
|
Antibodies to argininosuccinate synthase and related methods. Antibodies, and antigen-binding fra... |
|
|
Invention
|
Engineered chimeric pegylated adi and methods of use. Provided are chimeric arginine deiminases, ... |
|
2014
|
Invention
|
Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatm... |
